WO2018190630A1 - Composition for preventing, ameliorating or treating polycystic ovary syndrome-related diseases comprising ecklonia cava extract as active ingredient - Google Patents

Composition for preventing, ameliorating or treating polycystic ovary syndrome-related diseases comprising ecklonia cava extract as active ingredient Download PDF

Info

Publication number
WO2018190630A1
WO2018190630A1 PCT/KR2018/004237 KR2018004237W WO2018190630A1 WO 2018190630 A1 WO2018190630 A1 WO 2018190630A1 KR 2018004237 W KR2018004237 W KR 2018004237W WO 2018190630 A1 WO2018190630 A1 WO 2018190630A1
Authority
WO
WIPO (PCT)
Prior art keywords
polycystic ovary
ovary syndrome
ecklonia cava
extract
related diseases
Prior art date
Application number
PCT/KR2018/004237
Other languages
French (fr)
Korean (ko)
Inventor
이혜원
고병섭
양현
편보정
Original Assignee
한국 한의학 연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국 한의학 연구원 filed Critical 한국 한의학 연구원
Publication of WO2018190630A1 publication Critical patent/WO2018190630A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/202—Algae extracts

Definitions

  • the present invention relates to a composition for the prevention, improvement or treatment of polycystic ovary syndrome-related diseases comprising the Ecklonia cava extract as an active ingredient.
  • Polycystic ovary syndrome is an endocrine metabolism that affects 4-12% of women of childbearing age.
  • the diagnostic criteria for polycystic ovary syndrome presented by the National Institutes of Health in 1990, require both chronic ovulation and clinical or biochemical devogenic hyperglycemia.
  • the diagnostic criteria of the European / US Reproductive Endocrinology Association, revised in 2003 consisted of three types of chronic ovulation, clinical or biochemical hyperandrogenemia, and ten small follicles with a bead-shaped beads along the edge of the enlarged ovary. When two or more of the criteria are satisfied, it is defined as polycystic ovary syndrome.
  • polycystic ovary syndrome The cause of polycystic ovary syndrome is not yet clear. As with other complications, the development of polycystic ovary syndrome is believed to have both genetic and environmental factors. As the technique developed, the focus of primary pathophysiology shifted from the ovary to the hypothalamus-pituitary axis, and then to the deficiency of insulin action. Although studies on the association between various genetic factors and polycystic ovary syndrome have been reported, there is no clinically applicable genetic test.
  • Symptoms of polycystic ovary syndrome include (1) oligomenorrhea or amenorrhea, (2) hyperandrogenism and / or hyperandrogenemia, and (3) morphological polycystic ovary morphology. )to be.
  • oligomenorrhea or amenorrhea oligomenorrhea or amenorrhea
  • hyperandrogenism and / or hyperandrogenemia oligomenorrhea or amenorrhea
  • hyperandrogenism and / or hyperandrogenemia morphological polycystic ovary morphology.
  • premature ovarian failure occurs when ovarian function does not function normally and is classified as ovulatory cycle insufficiency, luteal insufficiency, or ovulation cycle insufficiency. do.
  • Ovulation cycles are also physiological in puberty and menopause, but infertile in mature women.
  • Progesterone insufficiency causes degeneration of the corpus luteum function quickly, causing infertility and miscarriage.
  • Ovulation cycle negativity is thought to be due to an abnormality of the follicle length because it is more than just the length of the cycle.
  • ovarian insufficiency can basically appear as a menopausal symptom when the age comes to menopause, but abnormally under 40 years of age, such symptoms may cause difficulty in pregnancy. The worsening of symptoms in these conditions leads to premature menopause.
  • menopause begins with menopause and postmenopausal women are at risk for many diseases due to hormonal imbalances, calcium deficiency and increased oxidative stress in the body.
  • diseases such as coronary artery disease, osteoporosis, Alzheimer's disease increases rapidly due to estrogen change in menopause, and in particular, the decrease in estrogen after menopause causes rapid bone loss.
  • Ecklonia cava is a seaweed belonging to the seaweed family and lives in the southern coastal area including South Korea's East Sea and Jeju Island.
  • Ecklonia pollen contains a lot of phlorotannin called polyphenol.
  • the Ecklonia cava containing a large amount of a strong antioxidant active material such as phlorotannin is attracting attention as a new functional material.
  • Ecklonia pollen contains antioxidants such as alpha-tocopherol. Studies on the bioactive components of Ecklonia cava and their use are underway.
  • Kim Jin-ah and Lee Jong-mi describe the antioxidant activity and whitening effect of Ecklonia phlorotannin in a research paper (Kim et al., Food Sci. Biotechnol. 2004. Vol 13, pages 476-480). Journal of the Korean Home Economics Association, 2004. Vol. 42. No. 5, pages 193-203), has also been reported on the antioxidant effect by heat treatment or extraction method.
  • the present invention is derived by the above requirements, the present invention provides a composition for the prevention, improvement or treatment of polycystic ovary syndrome-related diseases comprising the Ecklonia cava extract as an active ingredient, Ecklonia cava extract is an active ingredient of the present invention It has a regulating activity of androgen DHEA (Dehydroepiandrosterone), decreases blood luteinizing hormone / follicle stimulating hormone ratio, increases blood follicular stimulating hormone, testosterone and ovarian follicle The present invention was completed by confirming that there was an effect of reducing the number of follicular cysts.
  • Ecklonia cava extract is an active ingredient of the present invention
  • the present invention is Ecklonia cava ) provides a pharmaceutical composition for the prevention or treatment of polycystic ovary syndrome-related diseases comprising the extract as an active ingredient.
  • the present invention is Ecklonia cava ) Provides a health functional food composition for preventing or improving diseases related to polycystic ovary syndrome (polycystic ovary syndrome) comprising the extract as an active ingredient.
  • the present invention relates to a composition for the prevention, improvement or treatment of polycystic ovary syndrome-related diseases comprising the Ecklonia cava extract as an active ingredient.
  • Ecklonia cava extract the active ingredient of the present invention, has a regulating activity of androgen DHEA (Dehydroepiandrosterone), reduces blood luteinizing hormone / follicle stimulating hormone ratio, increases blood follicular stimulating hormone, and testosterone in blood
  • related drugs such as cystic ovarian syndrome, amenorrhea, hypermenorrhea, dysfunctional uterine bleeding, early menopause, infertility, ovarian failure and endometriosis It can be widely used in the functional food industry.
  • Con is a control group, cells without any treatment
  • FOR is a cell group treated with 10 ⁇ M of Forskolin to induce excessive secretion of androgens
  • MET is a positive control cell treated with 1 mM metformin.
  • PIO is a positive control cell treated with 10 ⁇ M pioglitazone.
  • Figure 2 is the result of confirming the expression level of the protein involved in the production of androgen DHEA (Dehydroepiandrosterone) using the human adrenal cell line (H295R) of the Ecklonia cava extract of the present invention by Western blot.
  • androgen DHEA Dehydroepiandrosterone
  • H295R human adrenal cell line
  • Figure 3 is to administer the Ecklonia cava extract according to the present invention in a PCOS animal model, confirming the effect of reducing the luteinizing hormone / follicle stimulating hormone ratio in the blood.
  • CON is a negative control group
  • PCOS is a PCOS group that abnormally increased the luteinizing hormone / follicle stimulating hormone ratio by administering letrozole
  • PCOS + EC500 is a group receiving letrozole and Ecklonia cava extract PCOS + positive was administered with 1 mg / kg / BW letrozole and 0.1 mg / kg / BW sustained release formulation for 2 weeks in the first half of the total experimental period of 4 weeks, and letrozole for the second 2 weeks.
  • the natural recovery group is a positive control group.
  • * Indicates a statistically significant increase in blood luteinizing hormone / follicular stimulating hormone ratio in the group of letrozole compared to CON, p ⁇ 0.05; # Shows that the ratio of luteinizing hormone / follicle stimulating hormone in blood was significantly decreased in the group treated with letrozole and Ecklonia cava extract, or the natural recovery group after letrozole treatment. , # Is p ⁇ 0.05.
  • Figure 4 is administered to the PCOS animal model of the Ecklonia cava extract according to the present invention, confirming the increase of follicular stimulating hormone (follicular stimulating hormone).
  • CON is a negative control group, normal group
  • PCOS is a PCOS group that abnormally reduced follicular stimulating hormone by administering letrozole
  • PCOS + EC500 is a group of letrozole and Ecklonia cava extract
  • PCOS + positive was administered with 1 mg / kg / BW letrozole and 0.1 mg / kg / BW sustained release formulation for 2 weeks in the first half of the total experimental period of 4 weeks, and letrozole for the second 2 weeks.
  • the natural recovery group, except for the administration of) is a positive control group.
  • Figure 5 is to administer the Ecklonia cava extract according to the present invention in a PCOS animal model, confirming the testosterone (testosterone) reduction effect.
  • CON is the negative control group, normal group
  • PCOS is the PCOS group that abnormally increased testosterone by administering letrozole
  • PCOS + EC500 is the administration group of letrozole and Ecklonia cava extract
  • PCOS + positive was administered with 1 mg / kg / BW letrozole and 0.1 mg / kg / BW sustained release formulation for two weeks in the first two weeks of the total experimental period, and for the second two weeks of letrozole. It is a positive control group, except for the natural recovery group.
  • the present invention is Ecklonia cava ) relates to a pharmaceutical composition for the prevention or treatment of polycystic ovary syndrome-related diseases comprising the extract as an active ingredient.
  • the Ecklonia cava extract may be prepared by a method comprising the following steps, but is not limited thereto:
  • step (3) concentrating and drying the filtered extract of step (2) to produce an extract.
  • the extraction solvent in step (1) is preferably selected from water, C 1 ⁇ C 4 lower alcohol or a mixture thereof, more preferably water, but is not limited thereto.
  • the extraction method may use all conventional methods known in the art, such as filtration, hot water extraction, immersion extraction, reflux cooling extraction and ultrasonic extraction.
  • the extraction solvent is preferably extracted by adding 1 to 20 times the weight of the dried Ecklonia cava, more preferably 5 to 15 times, and even more preferably 10 times.
  • Extraction temperature is preferably 60 ⁇ 100 °C but is not limited thereto.
  • the extraction time is preferably 1 to 48 hours, more preferably 1 to 24 hours, most preferably 3 hours is not limited thereto.
  • the concentration in step (3) is preferably, but not limited to, using a vacuum rotary concentrator or a vacuum rotary evaporator.
  • drying is preferably carried out under reduced pressure drying, vacuum drying, boiling drying, spray drying or lyophilization, more preferably freeze drying but not limited thereto.
  • the polycystic ovary syndrome is characterized by ovarian failure, and the polycystic ovary syndrome-related disease is preferably at least one selected from fossadrogenemia, amenorrhea, hypermenorrhea, dysfunctional uterine bleeding, premature menopause, infertility and endometriosis. It is not.
  • Ecklonia cava extract may further include a pharmaceutically acceptable carrier, excipient or diluent.
  • the pharmaceutical composition of the present invention may be administered orally or parenterally, and when parenteral administration, it is preferable to select external or intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular injection methods. Preferably it is used for external skin.
  • compositions of the present invention may be formulated using diluents or excipients, such as fillers, extenders, binders, wetting agents, disintegrants, surfactants and the like.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may comprise at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin.
  • excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin.
  • lubricants such as magnesium stearate, talc and the like are also used.
  • Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. have.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycero gelatin and the like can be used.
  • composition according to the invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level means the type, severity, and activity of the patient's disease. , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of the drug, and other factors well known in the medical arts.
  • the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can achieve the maximum effect with a minimum amount without side effects, which can be readily determined by one skilled in the art.
  • the dosage of the composition of the present invention can be used in a variety of ranges depending on the weight, age, sex, health, diet, time of administration, administration method, excretion rate and severity of the patient.
  • the present invention is Ecklonia cava ) relates to a health functional food composition for the prevention or improvement of polycystic ovary syndrome-related diseases comprising the extract as an active ingredient.
  • the polycystic ovary syndrome is characterized by ovarian failure, and the polycystic ovary syndrome-related disease is preferably at least one selected from fossadrogenemia, amenorrhea, hypermenorrhea, dysfunctional uterine bleeding, premature menopause, infertility and endometriosis. It is not.
  • Health functional food composition for the prevention or improvement of ovarian dysfunction related diseases comprising the Ecklonia cava extract as an active ingredient is prepared by any one selected from powders, granules, pills, tablets, capsules, candy, syrups and beverages, or added as a component of food Can be prepared, and can be appropriately prepared according to a conventional method.
  • Examples of foods to which the Ecklonia cava extract of the present invention may be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, various soups, beverages, Tea, drink, alcoholic beverages and vitamin complexes may be any one of the forms selected, including all the health functional foods in the conventional sense.
  • the dietary supplement includes various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and salts thereof, alkonic acid and salts thereof, organic acids, protective colloidal thickeners. , pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. Others may contain pulp for the production of natural fruit juices and vegetable drinks. These components can be used independently or in combination.
  • the dietary supplement composition of the present invention may contain various flavors or natural carbohydrates as additional ingredients.
  • the natural carbohydrates are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol.
  • sweetening agent natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used.
  • the Ecklonia cava used in one embodiment of the present invention was used to purchase the Ecklonia cava collected or distributed in Jeju.
  • H295R human adrenal cell line
  • Forskolin Forskolin
  • androgen DHEA Dehydroepiandrosterone
  • 50 ⁇ g / ml of Ecklonia cava extract was treated, and 1 mM metformin (MET) and 10 ⁇ M pioglitazone (PIO) were used as positive controls.
  • MET metformin
  • PIO pioglitazone
  • mice used as experimental animals were supplied from Orient Bio, Inc. The experimental animals were used after 7 days of adaptation at the joint animal laboratory breeding facility of Chungnam National University.
  • the experimental method was deliberated by the Animal Experimental Ethics Committee of Chungnam National University.
  • the breeding and maintenance of experimental animals was carried out according to the animal care and use regulations of Chungnam National University Animal Lab.
  • Two dogs were housed in an individually ventilated cage (IVC) in a nursery that was kept constant in light and dark cycles.
  • IVC individually ventilated cage
  • Ecklonia cava extract of the present invention is characterized by changes in blood luteinizing hormone / follicle stimulating hormone ratio (LH / FSH ratio), blood follicular stimulating hormone (blood follicular stimulating hormone), blood testosterone, and ovarian follicular cyst The effect was investigated.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a composition for preventing, ameliorating or treating polycystic ovary syndrome-related diseases comprising an Ecklonia cava extract as an active ingredient. The Ecklonia cava extract, which is an active ingredient of the present invention, has an activity of regulating the production of androgen dehydroepiandrosterone (DHEA), an effect of reducing the luteinizing hormone/follicle stimulating hormone ratio in the blood, an effect of increasing follicular stimulating hormone in the blood, and an effect of reducing blood testosterone and the number of ovarian follicular cysts. Therefore, the Ecklonia cava extract can be effectively used for preventing, ameliorating or treating one or more diseases selected from hyperandrogenism, amenorrhea, hypomenorrhea, dysfunctional uterine bleeding, premature menopause, infertility, ovarian failure, and endometriosis, which are polycystic ovary syndrome-related diseases.

Description

감태 추출물을 유효성분으로 포함하는 다낭성 난소 증후군 관련 질환의 예방, 개선 또는 치료용 조성물Composition for the prevention, improvement or treatment of polycystic ovary syndrome-related diseases comprising Ecklonia cava extract as an active ingredient
본 발명은 감태 추출물을 유효성분으로 포함하는 다낭성 난소 증후군 관련 질환의 예방, 개선 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for the prevention, improvement or treatment of polycystic ovary syndrome-related diseases comprising the Ecklonia cava extract as an active ingredient.
다낭성 난소 증후군은 가임 여성의 4~12%가 영향을 받고 있는 내분비대사 질환이다. 1990년 미국 국립보건원(National Institutes of Health)에서 제시한 다낭성 난소 증후군의 진단 기준은 만성 무배란 및 임상적 또는 생화학적 고안드로겐혈증의 두 가지 모두를 요구한다. 반면 2003년 개정된 유럽/미국 생식내분비학회 연합의 진단 기준은 만성 무배란, 임상적 또는 생화학적 고안드로겐혈증, 그리고 커진 난소의 가장자리를 따라 10여 개의 작은 난포가 염주모양을 하고 있는 양상의 세 가지 기준 중에서 두 가지 이상을 만족하는 경우에 다낭성 난소 증후군으로 정의하고 있다.Polycystic ovary syndrome is an endocrine metabolism that affects 4-12% of women of childbearing age. The diagnostic criteria for polycystic ovary syndrome, presented by the National Institutes of Health in 1990, require both chronic ovulation and clinical or biochemical devogenic hyperglycemia. On the other hand, the diagnostic criteria of the European / US Reproductive Endocrinology Association, revised in 2003, consisted of three types of chronic ovulation, clinical or biochemical hyperandrogenemia, and ten small follicles with a bead-shaped beads along the edge of the enlarged ovary. When two or more of the criteria are satisfied, it is defined as polycystic ovary syndrome.
아직 다낭성 난소 증후군의 발병 원인은 명확히 밝혀지지 않고 있다. 다른 복합성 질환들과 마찬가지로 다낭성 난소 증후군의 발병에도 유전적 인자 및 환경적 인자가 모두 작용하는 것으로 여겨진다. 연구의 기법이 발달해 가면서 일차적 병태 생리의 초점은 난소에서 시상하부-뇌하수체 축으로 옮겨갔고, 이후 인슐린 작용의 결함 쪽으로 옮겨가고 있는 추세이다. 다양한 유전학적 요인과 다낭성 난소 증후군의 연관성에 관한 연구 결과들이 보고되고 있지만, 아직까지 임상적으로 적용 가능한 유전학적 검사는 없는 상태이다.The cause of polycystic ovary syndrome is not yet clear. As with other complications, the development of polycystic ovary syndrome is believed to have both genetic and environmental factors. As the technique developed, the focus of primary pathophysiology shifted from the ovary to the hypothalamus-pituitary axis, and then to the deficiency of insulin action. Although studies on the association between various genetic factors and polycystic ovary syndrome have been reported, there is no clinically applicable genetic test.
다낭성 난소 증후군의 증상으로는 (1) 희발월경(oligomenorrhea)이나 무월경(amenorrhea), (2) 안드로겐과다혈증(hyperandrogenism) 및/또는 남성호르몬과다증 (hyperandrogenemia), (3) 형태학적인 다낭(polycystic ovary morphology)이다. 이외에도 나이와 몸무게를 대상으로 한 조사를 토대로 살펴보면 대조군과 비교해서 약 50%의 다낭성 난소 증후군 여성에게서 혈청 내 황체형성 호르몬의 과분비(luteinizing hormone(LH) hypersecretion), 인슐린 저항성(insulin resistance), 및 보상적 고인슐린혈증(compensatory hyperinsulinemia) 등의 생화학적 특징이 공통적으로 나타난다.Symptoms of polycystic ovary syndrome include (1) oligomenorrhea or amenorrhea, (2) hyperandrogenism and / or hyperandrogenemia, and (3) morphological polycystic ovary morphology. )to be. In addition, based on age and weight surveys, approximately 50% of women with polycystic ovary syndrome compared to controls had luteinizing hormone (LH) hypersecretion, insulin resistance, and compensation in serum. Biochemical features such as compensatory hyperinsulinemia are common.
다낭성 난소 증후군 관련 질환의 일례로, 난소 부전증(premature ovarian failure)은 난소기능이 정상적으로 작용하지 않는 경우에 발생하는 것으로서 배란성 주기 부정증(不整症), 황체 기능 부전증, 무배란성 주기 부정증으로 분류한다. 무배란성 주기증은 사춘기, 갱년기에서는 생리적으로도 나타나지만 성숙부인에서는 불임이 된다. 황체 기능 부전증은 황체 기능의 퇴행이 빨라, 불임과 유산의 원인이 된다. 배란성 주기 부정증은 주기의 길이에만 이상이기 때문에 난포기의 길이의 이상 때문으로 보고 있다. 이러한 난소 부전증은 기본적으로 연령이 많아져 폐경이 될 시기가 오면 폐경기 증상으로 나타날 수도 있지만 비정상적으로 40세 미만에서 이러한 증상이 나타나 임신에 어려움이 발생하기도 한다. 이러한 상태에서 증상이 더 악화되면 조기폐경으로 이어지게 된다.As an example of polycystic ovarian syndrome-related diseases, premature ovarian failure occurs when ovarian function does not function normally and is classified as ovulatory cycle insufficiency, luteal insufficiency, or ovulation cycle insufficiency. do. Ovulation cycles are also physiological in puberty and menopause, but infertile in mature women. Progesterone insufficiency causes degeneration of the corpus luteum function quickly, causing infertility and miscarriage. Ovulation cycle negativity is thought to be due to an abnormality of the follicle length because it is more than just the length of the cycle. These ovarian insufficiency can basically appear as a menopausal symptom when the age comes to menopause, but abnormally under 40 years of age, such symptoms may cause difficulty in pregnancy. The worsening of symptoms in these conditions leads to premature menopause.
또한, 난소 기능의 감소로 야기된 시상하부-뇌하수체-난소로 이어지는 성선 축의 기능 실조가 원인이 되고 이로 인하여 성호르몬, 지질 및 심혈관계 대사, 골대사, 기억 작용 등의 신체 및 정신적인 변화가 나타난다. 갱년기의 시작은 폐경과 더불어 시작되며 폐경기 여성은 호르몬 불균형과 칼슘 결핍 및 체내 산화적 스트레스 증가로 여러 질병의 위험에 처하게 된다. 즉, 폐경기의 에스트로겐 변화로 관상동맥 질환, 골다공증, 알츠하이머 등 질환의 발병률은 급증하게 되고, 특히 폐경기 이후 에스트로겐 감소는 급속한 골 손실을 초래하게 된다.In addition, dysfunction of the gonadotrophy leading to the hypothalamus-pituitary-ovary caused by a decrease in ovarian function is caused, resulting in physical and mental changes such as sex hormones, lipid and cardiovascular metabolism, bone metabolism, and memory. Menopause begins with menopause and postmenopausal women are at risk for many diseases due to hormonal imbalances, calcium deficiency and increased oxidative stress in the body. In other words, the incidence of diseases such as coronary artery disease, osteoporosis, Alzheimer's disease increases rapidly due to estrogen change in menopause, and in particular, the decrease in estrogen after menopause causes rapid bone loss.
한편, 감태는 미역과에 속하는 해조류로서 우리나라 동해 남부와 제주도를 포함한 남해안 일대에 서식한다. 감태에는 바다식물의 폴리페놀(polyphenol)이라는 플로로타닌(phlorotannin)이 많이 함유되어 있다. 특히 최근 노화를 비롯한 여러 가지 성인병의 원인이 free-radical에 의한 산화임이 밝혀지면서, 플로로타닌(phlorotannin)과 같은 강한 항산화 활성 물질을 다량 함유한 감태가 새로운 기능성 소재로서 주목을 받고 있다. 감태에는 플로로타닌(phlorotannin) 외에도 알파-토코페롤과 같은 항산화물질도 함유되어있다. 감태의 생리활성 성분과 이의 이용에 대한 연구가 진행되고 있다. 김진아, 이종미 등은 연구 논문 (Kim et al., Food Sci. Biotechnol. 2004. Vol 13, 페이지 476-480)에 감태 phlorotannin의 항산화 활성과 미백효과 등에 대하여 개시하고 있고, 또 다른 연구논문 (김진아 등. 대한가정학회지, 2004. Vol. 42. No. 5, 페이지 193-203)에 열처리 또는 추출 방법에 의한 항산화효능 효과에 대한 연구도 보고된 바 있다.On the other hand, Ecklonia cava is a seaweed belonging to the seaweed family and lives in the southern coastal area including South Korea's East Sea and Jeju Island. Ecklonia pollen contains a lot of phlorotannin called polyphenol. In particular, as it has recently been found that the cause of various adult diseases including aging is free-radical oxidation, the Ecklonia cava containing a large amount of a strong antioxidant active material such as phlorotannin is attracting attention as a new functional material. In addition to phlorotannin, Ecklonia pollen contains antioxidants such as alpha-tocopherol. Studies on the bioactive components of Ecklonia cava and their use are underway. Kim Jin-ah and Lee Jong-mi describe the antioxidant activity and whitening effect of Ecklonia phlorotannin in a research paper (Kim et al., Food Sci. Biotechnol. 2004. Vol 13, pages 476-480). Journal of the Korean Home Economics Association, 2004. Vol. 42. No. 5, pages 193-203), has also been reported on the antioxidant effect by heat treatment or extraction method.
본 발명의 감태 추출물의 의약 용도에 관한 종래기술로는 한국공개특허 제2013-0028261호에 감태 추출물을 유효성분으로 함유하는 파킨슨 질환의 예방 또는 치료용 조성물에 관한 기술이 알려져 있으나, 본 발명의 감태 추출물을 유효성분으로 포함하는 다낭성 난소 증후군 관련 질환의 예방, 개선 또는 치료용 조성물에 대해서는 알려진 바 없다.As a prior art of the pharmaceutical use of the Ecklonia cava extract of the present invention, a technique related to the composition for preventing or treating Parkinson's disease containing Ecklonia cava extract as an active ingredient is known in Korea Patent Publication No. 2013-0028261, There is no known composition for preventing, ameliorating or treating polycystic ovary syndrome-related diseases including the extract as an active ingredient.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명은 감태 추출물을 유효성분으로 포함하는 다낭성 난소 증후군 관련 질환의 예방, 개선 또는 치료용 조성물을 제공하고, 본 발명의 유효성분인 감태 추출물은 안드로겐 DHEA(Dehydroepiandrosterone)의 생성 조절 활성이 있으며, 혈중 황체형성호르몬(luteinizing hormone)/난포자극호르몬 비율 감소 효과, 혈중 난포자극호르몬(follicular stimulating hormone) 증가 효과, 혈중 테스토스테론(testosterone) 및 난소 내 난포낭(follicular cyst) 수 감소 효과가 있다는 것을 확인함으로써, 본 발명을 완성하였다.The present invention is derived by the above requirements, the present invention provides a composition for the prevention, improvement or treatment of polycystic ovary syndrome-related diseases comprising the Ecklonia cava extract as an active ingredient, Ecklonia cava extract is an active ingredient of the present invention It has a regulating activity of androgen DHEA (Dehydroepiandrosterone), decreases blood luteinizing hormone / follicle stimulating hormone ratio, increases blood follicular stimulating hormone, testosterone and ovarian follicle The present invention was completed by confirming that there was an effect of reducing the number of follicular cysts.
상기 목적을 달성하기 위하여, 본 발명은 감태(Ecklonia cava) 추출물을 유효성분으로 포함하는 다낭성난소 증후군(polycystic ovary syndrome) 관련 질환의 예방 또는 치료용 약학 조성물을 제공한다.In order to achieve the above object, the present invention is Ecklonia cava ) provides a pharmaceutical composition for the prevention or treatment of polycystic ovary syndrome-related diseases comprising the extract as an active ingredient.
또한, 본 발명은 감태(Ecklonia cava) 추출물을 유효성분으로 포함하는 다낭성난소 증후군(polycystic ovary syndrome) 관련 질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention is Ecklonia cava ) Provides a health functional food composition for preventing or improving diseases related to polycystic ovary syndrome (polycystic ovary syndrome) comprising the extract as an active ingredient.
본 발명은 감태 추출물을 유효성분으로 포함하는 다낭성 난소 증후군 관련 질환의 예방, 개선 또는 치료용 조성물에 관한 것이다. 본 발명의 유효성분인 감태 추출물은 안드로겐 DHEA(Dehydroepiandrosterone)의 생성 조절 활성이 있으며, 혈중 황체형성호르몬/난포자극호르몬 비율 감소 효과, 혈중 난포자극호르몬(follicular stimulating hormone) 증가 효과, 혈중 테스토스테론(testosterone) 및 난소 내 난포낭(follicular cyst) 수 감소 효과가 있으므로, 다낭성 난소 증후군 관련 질환인 고안드로겐 혈증, 무월경, 과소월경, 기능 이상성 자궁출혈, 조기폐경, 난임, 난소부전 및 자궁내막증 등의 관련 의약품 또는 건강기능식품 산업에 널리 활용될 수 있다. The present invention relates to a composition for the prevention, improvement or treatment of polycystic ovary syndrome-related diseases comprising the Ecklonia cava extract as an active ingredient. Ecklonia cava extract, the active ingredient of the present invention, has a regulating activity of androgen DHEA (Dehydroepiandrosterone), reduces blood luteinizing hormone / follicle stimulating hormone ratio, increases blood follicular stimulating hormone, and testosterone in blood And because there is an effect of reducing the number of follicular cyst in the ovary, related drugs such as cystic ovarian syndrome, amenorrhea, hypermenorrhea, dysfunctional uterine bleeding, early menopause, infertility, ovarian failure and endometriosis It can be widely used in the functional food industry.
도 1은 인간 부신 세포주(H295R)을 이용한 본 발명에 따른 감태 물 추출물(감태 H)의 안드로겐 DHEA(Dehydroepiandrosterone) 생성 조절 효과를 확인한 결과이다. Con은 대조군로서, 아무것도 처리하지 않은 세포이고, FOR은 안드로겐의 과다 분비를 유도하기 위해 10μM의 포스콜린(Forskolin)을 처리한 세포군이며, MET는 1mM의 메트포르민(metformin)을 처리한 양성대조군의 세포이고, PIO는 10μM의 피오글리타존(pioglitazone)을 처리한 양성대조군의 세포이다. ***은 Con에 비해 포스콜린을 처리한 세포에서 안드로겐 DHEA 생성이 통계적으로 유의미하게 증가하였다는 것으로, p<0.001임을 의미하며, ##는 포스콜린 처리에 의해 증가된 안드로겐 DHEA가 본 발명의 감태 추출물의 처리에 의해 통계적으로 유의미하게 감소하였다는 것으로, p<0.01이다. 1 is a result confirming the effect of androgen DHEA (Dehydroepiandrosterone) production regulation of Ecklonia cava extract (Ecklonia cava) H according to the present invention using a human adrenal cell line (H295R). Con is a control group, cells without any treatment, FOR is a cell group treated with 10 μM of Forskolin to induce excessive secretion of androgens, and MET is a positive control cell treated with 1 mM metformin. PIO is a positive control cell treated with 10 μM pioglitazone. *** indicates statistically significant increase in androgen DHEA production in phospholine-treated cells compared to Con, p <0.001, and ## indicates that androgen DHEA increased by phospholine treatment It was statistically significantly reduced by the treatment of Ecklonia cava extract, p <0.01.
도 2는 본 발명의 감태 추출물의 인간 부신 세포주(H295R)을 이용한 안드로겐 DHEA(Dehydroepiandrosterone)의 생성에 관여하는 단백질의 발현량을 웨스턴 블랏으로 확인한 결과이다.Figure 2 is the result of confirming the expression level of the protein involved in the production of androgen DHEA (Dehydroepiandrosterone) using the human adrenal cell line (H295R) of the Ecklonia cava extract of the present invention by Western blot.
도 3은 본 발명에 따른 감태 추출물을 PCOS 동물모델에 투여하여, 혈중 황체형성호르몬/난포자극호르몬 비율의 감소 효과를 확인한 것이다. CON은 음성 대조군으로서 정상군이며, PCOS는 레트로졸(letrozole)을 투여하여 황체형성호르몬/난포자극호르몬 비율을 비정상적으로 증가시킨 PCOS군이며, PCOS+EC500은 레트로졸(letrozole) 및 감태 추출물의 투여군이고, PCOS+positive는 총 실험기간 4주 중, 전반부 2주 동안 1mg/kg/BW 레트로졸(letrozole) 투여 및 0.1mg/kg/BW 서방형 제형 삽입하고, 후반부 2주 동안은 레트로졸(letrozole)의 투여를 제외한 자연회복군으로 양성대조군이다. *은 CON에 비해 레트로졸(letrozole)을 투여한 군에서 혈중 황체형성호르몬/난포자극호르몬 비율이 통계적으로 유의미하게 증가하였다는 것으로, p<0.05임을 의미하며; #은 레트로졸(letrozole) 투여군 대비 레트로졸(letrozole) 및 감태 추출물의 투여군, 또는 레트로졸(letrozole) 처치 후 자연회복군의 혈중 황체형성호르몬/난포자극호르몬 비율이 통계적으로 유의미하게 감소하였다는 것으로, #는 p<0.05이다. Figure 3 is to administer the Ecklonia cava extract according to the present invention in a PCOS animal model, confirming the effect of reducing the luteinizing hormone / follicle stimulating hormone ratio in the blood. CON is a negative control group, PCOS is a PCOS group that abnormally increased the luteinizing hormone / follicle stimulating hormone ratio by administering letrozole, PCOS + EC500 is a group receiving letrozole and Ecklonia cava extract PCOS + positive was administered with 1 mg / kg / BW letrozole and 0.1 mg / kg / BW sustained release formulation for 2 weeks in the first half of the total experimental period of 4 weeks, and letrozole for the second 2 weeks. The natural recovery group, except for the administration of), is a positive control group. * Indicates a statistically significant increase in blood luteinizing hormone / follicular stimulating hormone ratio in the group of letrozole compared to CON, p <0.05; # Shows that the ratio of luteinizing hormone / follicle stimulating hormone in blood was significantly decreased in the group treated with letrozole and Ecklonia cava extract, or the natural recovery group after letrozole treatment. , # Is p <0.05.
도 4는 본 발명에 따른 감태 추출물을 PCOS 동물모델에 투여하여, 난포자극호르몬(follicular stimulating hormone)의 증가를 확인한 것이다. CON은 음성대조군으로서 정상군이며, PCOS는 레트로졸(letrozole)을 투여하여 난포자극호르몬(follicular stimulating hormone)을 비정상적으로 감소시킨 PCOS군이며, PCOS+EC500은 레트로졸(letrozole) 및 감태 추출물의 투여군이고, PCOS+positive는 총 실험기간 4주 중, 전반부 2주 동안 1mg/kg/BW 레트로졸(letrozole) 투여 및 0.1mg/kg/BW 서방형 제형 삽입하고, 후반부 2주 동안은 레트로졸(letrozole)의 투여를 제외한 자연회복군으로 양성대조군이다. *은 CON에 비해 레트로졸(letrozole)을 투여한 군에서 난포자극호르몬(follicular stimulating hormone)이 통계적으로 유의미하게 감소하였다는 것으로, p<0.05임을 의미하며, #은 레트로졸(letrozole) 투여군 대비 레트로졸(letrozole) 및 본 발명의 감태 추출물의 투여군 또는 레트로졸(letrozole) 처치 후 자연회복군의 난포자극호르몬(follicular stimulating hormone)이 통계적으로 유의미하게 증가하였다는 것으로, #는 p<0.05이다. Figure 4 is administered to the PCOS animal model of the Ecklonia cava extract according to the present invention, confirming the increase of follicular stimulating hormone (follicular stimulating hormone). CON is a negative control group, normal group, PCOS is a PCOS group that abnormally reduced follicular stimulating hormone by administering letrozole, PCOS + EC500 is a group of letrozole and Ecklonia cava extract PCOS + positive was administered with 1 mg / kg / BW letrozole and 0.1 mg / kg / BW sustained release formulation for 2 weeks in the first half of the total experimental period of 4 weeks, and letrozole for the second 2 weeks. The natural recovery group, except for the administration of), is a positive control group. * Indicates statistically significant decrease in follicular stimulating hormone in letrozole compared to CON, which means p <0.05, and # means retro compared to letrozole After treatment with letrozole and the Ecklonia cava extract of the present invention or letrozole treatment, follicular stimulating hormone of the natural recovery group was statistically significantly increased, # is p <0.05.
도 5는 본 발명에 따른 감태 추출물을 PCOS 동물모델에 투여하여, 테스트스테론(testosterone) 감소 효과를 확인한 것이다. CON은 음성대조군으로서 정상군이며, PCOS는 레트로졸(letrozole)을 투여하여 테스트스테론(testosterone)을 비정상적으로 증가시킨 PCOS군이며, PCOS+EC500은 레트로졸(letrozole) 및 감태 추출물의 투여군이고, PCOS+positive는 총 실험기간 4주 중, 전반부 2주 동안 1mg/kg/BW 레트로졸(letrozole) 투여 및 0.1mg/kg/BW 서방형 제형 삽입하고, 후반부 2주 동안은 레트로졸(letrozole)의 투여를 제외한 자연회복군으로 양성대조군이다. *은 CON에 비해 레트로졸(letrozole)을 투여한 군에서 테스트스테론(testosterone)이 통계적으로 유의미하게 증가하였다는 것으로, p<0.05임을 의미하며, #은 레트로졸(letrozole) 투여군 대비 레트로졸(letrozole) 및 본 발명의 감태 추출물의 투여군 또는 레트로졸(letrozole) 처치 후 자연회복군의 테스트스테론(testosterone)이 통계적으로 유의미하게 감소하였다는 것으로, #는 p<0.05이다. Figure 5 is to administer the Ecklonia cava extract according to the present invention in a PCOS animal model, confirming the testosterone (testosterone) reduction effect. CON is the negative control group, normal group, PCOS is the PCOS group that abnormally increased testosterone by administering letrozole, PCOS + EC500 is the administration group of letrozole and Ecklonia cava extract, PCOS + positive was administered with 1 mg / kg / BW letrozole and 0.1 mg / kg / BW sustained release formulation for two weeks in the first two weeks of the total experimental period, and for the second two weeks of letrozole. It is a positive control group, except for the natural recovery group. * Indicates statistically significant increase in testosterone (letosterole) in the group treated with letrozole compared to CON, which means p <0.05, and # means letrozole compared to the group treated with letrozole ( testosterone of the natural recovery group was significantly decreased after administration of letrozole) and Ecklonia cava extract of the present invention or letrozole. # is p <0.05.
본 발명은 감태(Ecklonia cava) 추출물을 유효성분으로 포함하는 다낭성 난소 증후군(polycystic ovary syndrome) 관련 질환의 예방 또는 치료용 약학 조성물에 관한 것이다. The present invention is Ecklonia cava ) relates to a pharmaceutical composition for the prevention or treatment of polycystic ovary syndrome-related diseases comprising the extract as an active ingredient.
상기 감태 추출물은 하기의 단계를 포함하는 방법에 의해 제조할 수 있으나, 이에 한정하지 않는다:The Ecklonia cava extract may be prepared by a method comprising the following steps, but is not limited thereto:
(1) 감태에 추출용매를 가하여 추출하는 단계;(1) extracting by adding an extraction solvent to the Ecklonia cava;
(2) 단계 (1)의 추출물을 여과하는 단계; 및 (2) filtering the extract of step (1); And
(3) 단계 (2)의 여과한 추출물을 농축하고 건조하여 추출물을 제조하는 단계. (3) concentrating and drying the filtered extract of step (2) to produce an extract.
상기 단계 (1)에서 추출용매는 물, C1~C4의 저급 알코올 또는 이들의 혼합물 중에서 선택하는 것이 바람직하며, 더 바람직하게는 물이지만 이에 한정하지 않는다.The extraction solvent in step (1) is preferably selected from water, C 1 ~ C 4 lower alcohol or a mixture thereof, more preferably water, but is not limited thereto.
상기 제조방법에 있어서, 추출방법은 여과법, 열수 추출, 침지 추출, 환류 냉각 추출 및 초음파 추출 등의 당 업계에 공지된 모든 통상적인 방법을 이용할 수 있다. 상기 추출용매는 건조된 감태 중량의 1~20배 첨가하여 추출하는 것이 바람직하며, 더 바람직하게는 5~15배 첨가하는 것이고, 더욱더 바람직하게는 10배 첨가하는 것이다. 추출온도는 60~100℃인 것이 바람직하나 이에 한정하지 않는다. 또한, 추출시간은 1~48시간인 것이 바람직하며, 1~24시간이 더욱 바람직하고, 3시간이 가장 바람직하나 이에 한정하지 않는다. 상기 방법에 있어서, 단계 (3)의 농축은 진공 회전 농축기 또는 진공회전증발기를 이용하는 것이 바람직하나 이에 한정하지 않는다. 또한, 건조는 감압건조, 진공건조, 비등건조, 분무 건조 또는 동결건조하는 것이 바람직하며, 더 바람직하게는 동결건조이나 이에 한정하지 않는다.In the above production method, the extraction method may use all conventional methods known in the art, such as filtration, hot water extraction, immersion extraction, reflux cooling extraction and ultrasonic extraction. The extraction solvent is preferably extracted by adding 1 to 20 times the weight of the dried Ecklonia cava, more preferably 5 to 15 times, and even more preferably 10 times. Extraction temperature is preferably 60 ~ 100 ℃ but is not limited thereto. In addition, the extraction time is preferably 1 to 48 hours, more preferably 1 to 24 hours, most preferably 3 hours is not limited thereto. In the above method, the concentration in step (3) is preferably, but not limited to, using a vacuum rotary concentrator or a vacuum rotary evaporator. In addition, drying is preferably carried out under reduced pressure drying, vacuum drying, boiling drying, spray drying or lyophilization, more preferably freeze drying but not limited thereto.
상기 다낭성 난소 증후군은 난소부전에 의한 것이 특징이며, 상기 다낭성 난소 증후군 관련 질환은 고안드로겐 혈증, 무월경, 과소월경, 기능 이상성 자궁출혈, 조기폐경, 난임 및 자궁내막증 중에서 선택된 하나 이상인 것이 바람직하지만 이에 한정하는 것은 아니다.The polycystic ovary syndrome is characterized by ovarian failure, and the polycystic ovary syndrome-related disease is preferably at least one selected from fossadrogenemia, amenorrhea, hypermenorrhea, dysfunctional uterine bleeding, premature menopause, infertility and endometriosis. It is not.
상기 감태 추출물 이외에 추가로 약제학적으로 허용가능한 담체, 부형제 또는 희석제를 더 포함할 수 있다. In addition to the Ecklonia cava extract, it may further include a pharmaceutically acceptable carrier, excipient or diluent.
본 발명의 약학 조성물은 경구 또는 비경구로 투여될 수 있으며, 비경구 투여 시 피부 외용 또는 복강 내, 직장, 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 주사 방식을 선택하는 것이 바람직하며, 가장 바람직하게는 피부 외용으로 사용한다.The pharmaceutical composition of the present invention may be administered orally or parenterally, and when parenteral administration, it is preferable to select external or intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular injection methods. Preferably it is used for external skin.
본 발명의 약학 조성물은 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형 제제는 하나 이상의 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 스테아린산 마그네슘, 탈크 등과 같은 윤활제들도 사용된다. 경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성 용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성 용제 및 현탁 용제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 61, 카카오지, 라우린지, 글리세로 젤라틴 등이 사용될 수 있다.The pharmaceutical compositions of the present invention may be formulated using diluents or excipients, such as fillers, extenders, binders, wetting agents, disintegrants, surfactants and the like. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may comprise at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin. In addition to simple excipients, lubricants such as magnesium stearate, talc and the like are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycero gelatin and the like can be used.
본 발명에 따른 조성물은 약제학적으로 유효한 양으로 투여한다. 본 발명에 있어서, "약제학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기한 요소들을 모두 고려하여 부작용없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The composition according to the invention is administered in a pharmaceutically effective amount. In the present invention, “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level means the type, severity, and activity of the patient's disease. , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of the drug, and other factors well known in the medical arts. The compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can achieve the maximum effect with a minimum amount without side effects, which can be readily determined by one skilled in the art.
본 발명의 조성물의 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설률 및 질환의 중증도에 따라 그 범위가 다양하게 사용할 수 있다.The dosage of the composition of the present invention can be used in a variety of ranges depending on the weight, age, sex, health, diet, time of administration, administration method, excretion rate and severity of the patient.
또한, 본 발명은 감태(Ecklonia cava) 추출물을 유효성분으로 포함하는 다낭성난소 증후군(polycystic ovary syndrome) 관련 질환의 예방 또는 개선용 건강기능식품 조성물에 관한 것이다. In addition, the present invention is Ecklonia cava ) relates to a health functional food composition for the prevention or improvement of polycystic ovary syndrome-related diseases comprising the extract as an active ingredient.
상기 다낭성 난소 증후군은 난소부전에 의한 것이 특징이며, 상기 다낭성 난소 증후군 관련 질환은 고안드로겐 혈증, 무월경, 과소월경, 기능 이상성 자궁출혈, 조기폐경, 난임 및 자궁내막증 중에서 선택된 하나 이상인 것이 바람직하지만 이에 한정하는 것은 아니다.The polycystic ovary syndrome is characterized by ovarian failure, and the polycystic ovary syndrome-related disease is preferably at least one selected from fossadrogenemia, amenorrhea, hypermenorrhea, dysfunctional uterine bleeding, premature menopause, infertility and endometriosis. It is not.
상기 감태 추출물을 유효성분으로 포함하는 난소 부전증 관련 질환의 예방 또는 개선용 건강기능식품 조성물은 분말, 과립, 환, 정제, 캡슐, 캔디, 시럽 및 음료 중에서 선택된 어느 하나로 제조하거나, 식품의 성분으로 첨가하여 제조될 수 있으며, 통상적인 방법에 따라 적절하게 제조될 수 있다. Health functional food composition for the prevention or improvement of ovarian dysfunction related diseases comprising the Ecklonia cava extract as an active ingredient is prepared by any one selected from powders, granules, pills, tablets, capsules, candy, syrups and beverages, or added as a component of food Can be prepared, and can be appropriately prepared according to a conventional method.
본 발명의 감태 추출물을 첨가할 수 있는 식품의 일례로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 중에서 선택된 어느 하나의 형태일 수 있으며, 통상적인 의미에서의 건강기능식품을 모두 포함한다.Examples of foods to which the Ecklonia cava extract of the present invention may be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, various soups, beverages, Tea, drink, alcoholic beverages and vitamin complexes may be any one of the forms selected, including all the health functional foods in the conventional sense.
상기 건강기능식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 및 천연 풍미제, 착색제 및 증진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알킨산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일 주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. The dietary supplement includes various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and salts thereof, alkonic acid and salts thereof, organic acids, protective colloidal thickeners. , pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. Others may contain pulp for the production of natural fruit juices and vegetable drinks. These components can be used independently or in combination.
본 발명의 건강기능식품 조성물은 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다.The dietary supplement composition of the present invention may contain various flavors or natural carbohydrates as additional ingredients. The natural carbohydrates are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used.
이하, 실시예를 이용하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로 본 발명의 범위가 이들에 의해 제한되지 않는다는 것은 당해 기술분야에서 통상의 지식을 가진 자에게 있어 자명한 것이다. Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for explaining the present invention in more detail, it is obvious to those skilled in the art that the scope of the present invention is not limited by them.
[시료 및 실험방법] [Sample and Experiment Method]
1. 시료1. Sample
본 발명의 일 실시예에서 사용하는 감태는 제주도에서 채취 또는 유통되는 감태를 구입하여 사용하였다.The Ecklonia cava used in one embodiment of the present invention was used to purchase the Ecklonia cava collected or distributed in Jeju.
1. 안드로겐 DHEA(Dehydroepiandrosterone) 생성량의 조절1. Control of the amount of androgen DHEA (Dehydroepiandrosterone) production
본 발명의 일 실시예에서는 인간 부신 세포주(H295R)에 10μM의 포스콜린(Forskolin)을 처리하여 안드로겐 DHEA(Dehydroepiandrosterone) 생성량을 증가시키고, 증가된 안드로겐 DHEA의 양을 감소시키는지 여부를 확인하기 위하여, 50㎍/㎖의 감태 물 추출물을 처리하였으며, 1mM의 메트포르민(metformin, MET) 및 10μM의 피오글리타존(pioglitazone, PIO)을 양성대조군으로 사용하였다.In one embodiment of the present invention, to treat the human adrenal cell line (H295R) 10μM of Forskolin (Forskolin) to increase the production of androgen DHEA (Dehydroepiandrosterone), to determine whether to reduce the amount of increased androgen DHEA, 50 μg / ml of Ecklonia cava extract was treated, and 1 mM metformin (MET) and 10 μM pioglitazone (PIO) were used as positive controls.
한편, 상기 물질들을 처리한 부신 세포주(H295R)에서의 CYP17A1, p-CREB 단백질의 발현 정도를 웨스턴 블랏으로 확인하였다(도 2).Meanwhile, the degree of expression of CYP17A1 and p-CREB proteins in the adrenal cell line (H295R) treated with the above substances was confirmed by Western blot (FIG. 2).
2. 혈중 황체형성호르몬/난포자극호르몬 비율(LH/FSH ratio), 혈중 난포자극호르몬(follicular stimulating hormone), 혈중 테스토스테론(testosterone), 및 난소 내 난포낭(follicular cyst) 수의 변화 확인2. Confirmation of changes in LH / FSH ratio, blood follicular stimulating hormone, blood testosterone, and follicular cyst count in ovary
실험동물로 사용된 암컷 SD 랫트는 ㈜오리엔트바이오에서 공급받아 사용하였다. 실험동물은 충남대학교 수의과대학의 공동동물실험실 사육시설에서 7일 동안 적응시킨 후 사용하였다.Female SD rats used as experimental animals were supplied from Orient Bio, Inc. The experimental animals were used after 7 days of adaptation at the joint animal laboratory breeding facility of Chungnam National University.
실험방법은 충남대학교 동물실험윤리위원회의 심의를 거쳤으며, 실험동물 사육 및 유지는 충남대학교 공동동물실험실의 동물 관리 및 사용 규정에 입각하여 온도 23±1℃, 습도 50±10% 내외, 12시간 명암주기로 일정하게 유지된 사육실에서 IVC(individually ventilated cage)에 2마리씩 넣어 사육하였다.The experimental method was deliberated by the Animal Experimental Ethics Committee of Chungnam National University. The breeding and maintenance of experimental animals was carried out according to the animal care and use regulations of Chungnam National University Animal Lab. Two dogs were housed in an individually ventilated cage (IVC) in a nursery that was kept constant in light and dark cycles.
본 발명의 감태 추출물이 혈중 황체형성호르몬/난포자극호르몬 비율(LH/FSH ratio), 혈중 난포자극호르몬(follicular stimulating hormone), 혈중 테스토스테론(testosterone), 및 난소 내 난포낭(follicular cyst) 수 변화에 대한 효과를 조사하였다. 1mg/kg/BW 레트로졸(letrozole)과 0.1mg/kg/BW 레트로졸 SR 펠릿이 혼합된 실험군(PCOS)과 1mg/kg/BW 레트로졸(letrozole)과 0.1mg/kg/BW 레트로졸 SR 펠릿과 500mg/kg/BW 감태(Ecklonia cava) 추출물이 혼합된 실험군(PCOS+EC500)과 총 실험기간 4주 중, 전반부 2주 동안 1mg/kg/BW 레트로졸(letrozole) 투여 및 0.1mg/kg/BW 서방형 제형 삽입하고, 후반부 2주 동안은 레트로졸(letrozole)의 투여를 제외한 자연회복군(PCOS+positive)을 사용하여 혈중 황체형성호르몬/난포자극호르몬 비율(LH/FSH ratio), 혈중 난포자극호르몬(follicular stimulating hormone), 혈중 테스토스테론(testosterone), 및 난소 내 난포낭(follicular cyst) 수 활성 변화를 조사하였다.Ecklonia cava extract of the present invention is characterized by changes in blood luteinizing hormone / follicle stimulating hormone ratio (LH / FSH ratio), blood follicular stimulating hormone (blood follicular stimulating hormone), blood testosterone, and ovarian follicular cyst The effect was investigated. Experimental group mixed with 1 mg / kg / BW letrozole and 0.1 mg / kg / BW letrozole SR pellets (PCOS) and 1 mg / kg / BW letrozole and 0.1 mg / kg / BW letrozole SR pellets With 500mg / kg / BW Ecklonia ( Ecklonia cava ) mixed with the experimental group (PCOS + EC500) and 1mg / kg / BW letrozole administration and 0.1mg / kg / BW sustained release formulation for 2 weeks in the first half of the total experimental period of 4 weeks, and the latter part 2 During the week, the LH / FSH ratio, blood follicular stimulating hormone, and blood were obtained using the natural recovery group (PCOS + positive), except for letrozole. Testosterone and ovarian follicular cyst number activity changes were investigated.
실시예Example 1.  One. 감태Ecklonia 추출물의 제조 Preparation of Extract
건조한 감태 시료양에 대하여 10~15배의 100%(v/v) 물을 첨가하고, 100℃에서 3시간 환류추출하여 감태 추출액을 수득하였다. 상기 수득한 감태 추출액을 0.4㎛ 필터로 감압여과한 후, 진공회전농축기로 농축하여 동결건조기를 이용하여 동결건조하였다.10-15 times 100% (v / v) water was added to the dried Ecklonia cava extract, and reflux extraction was performed at 100 ° C. for 3 hours to obtain Ecklonia cava extract. The obtained Ecklonia cava extract was filtered under reduced pressure with a 0.4 μm filter, concentrated in a vacuum rotary concentrator, and lyophilized using a freeze dryer.
실시예 2. 감태 추출물의 안드로겐 DHEA( dehydroepiandrosterone )의 함량 조절 효과 확인 Example 2. Checking the effect of adjusting the content of androgen DHEA ( dehydroepiandrosterone ) of Ecklonia cava extract
50㎍/㎖의 감태 추출물을 인간 부신 세포주(H295R)에 처리한 결과, 도 1에 나타난 바와 같이, 안드로겐 DHEA(dehydroepiandrosterone) 생성이 유의미한 농도로 억제되는 것을 확인할 수 있었다. 1mM 메트포르민을 처리한 군에서도 감태 추출물과 유사한 안드로겐 DHEA(Dehydroepiandrosterone) 생성 조절 효과를 나타냈으나, 메트포르민의 경우 다낭성 난소 증후군 환자에게 인슐린 저항성을 낮추고 혈당을 조절하기 위해 사용되는 물질이나, 난소 기능 저하 현상을 유발할 수 있다고도 알려져 있다.As a result of treatment of 50 μg / ml Ecklonia cava extract to the human adrenal cell line (H295R), as shown in FIG. 1, it was confirmed that androgen dehydroepiandrosterone (DHEA) production was inhibited at a significant concentration. In the 1mM metformin-treated group, the effect of androgen dehydroepiandrosterone (DHEA) production was similar to the Ecklonia cava extract, but metformin was used to reduce insulin resistance and control blood sugar in patients with polycystic ovary syndrome. It is also known to cause.
한편, 본 발명의 감태 추출물을 처리한 세포에서 안드로겐 DHEA 함량을 조절하는 것으로 알려진 단백질인 CYP17A1 및 p-CREB 단백질의 함량이 감소한 것을 확인하였다(도 2).On the other hand, in the cells treated with Ecklonia cava extract of the present invention, it was confirmed that the contents of the CYP17A1 and p-CREB proteins, which are known to regulate androgen DHEA content, were reduced (FIG. 2).
실시예 3. 감태 추출물의 혈중 황체형성호르몬/난포자극호르몬 비율( LH / FSH ratio) 변화 확인 Example 3 Progesterone Hormone / Follicle Stimulating Hormone Ratio in the Ecklonia cava Extract ( LH / FSH change)
1mg/kg/BW 레트로졸(letrozole)과 0.1mg/kg/BW 레트로졸 SR 펠릿이 혼합된 실험군(PCOS)과 1mg/kg/BW 레트로졸(letrozole)과 0.1mg/kg/BW 레트로졸 SR 펠릿과 500mg/kg/BW 감태 추출물(Ecklonia cava)이 혼합된 실험군(PCOS+EC500)과 총 실험기간 4주 중, 전반부 2주 동안 1mg/kg/BW 레트로졸(letrozole) 투여 및 0.1mg/kg/BW 서방형 제형 삽입하고, 후반부 2주 동안은 레트로졸(letrozole)의 투여를 제외한 자연회복군(PCOS+positive)을 사용하여 혈중 황체형성호르몬/난포자극호르몬 비율(LH/FSH ratio) 변화를 확인한 결과, 도 3에 개시한 바와 같이, PCOS 유도된 1mg/kg/BW 레트로졸(letrozole)의 투여군(PCOS)에서는 혈중 황체형성호르몬/난포자극호르몬 비율(LH/FSH ratio)이 통계적으로 유의미하게 증가하였고, 본 발명의 500mg/kg/BW 감태(Ecklonia cava) 추출물이 혼합된 실험군(PCOS+EC500)과 0.1mg/kg/BW 레트로졸(letrozole) SR 펠릿에 1mg/kg/BW 레트로졸(letrozole) 처치 후 자연회복군이 혼합된 실험군(PCOS+positive)에서는 혈중 황체형성호르몬/난포자극호르몬 비율(LH/FSH ratio)이 감소하였다는 것을 확인하였다(도 3). Experimental group mixed with 1 mg / kg / BW letrozole and 0.1 mg / kg / BW letrozole SR pellets (PCOS) and 1 mg / kg / BW letrozole and 0.1 mg / kg / BW letrozole SR pellets 500mg / kg / BW Ecklonia cava extract ( Ecklonia cava ) mixed with the experimental group (PCOS + EC500) and 1mg / kg / BW letrozole administration and 0.1mg / kg / BW sustained release formulation for two weeks in the first half of the four weeks of the experimental period, and the second two weeks As a result of confirming the change in blood luteinizing hormone / follicle stimulating hormone ratio (LH / FSH ratio) using a natural recovery group (PCOS + positive) except administration of letrozole, as shown in FIG. In the PCOS induced 1 mg / kg / BW letrozole administration group (PCOS), the LH / FSH ratio was significantly increased in blood, and 500 mg / kg / BW of the present invention. Ecklonia cava ) Experimental group (PCOS + EC500) and 0.1mg / kg / BW letrozole SR pellets treated with 1mg / kg / BW letrozole treatment group, natural recovery group mixed (PCOS + positive) ), The blood luteinizing hormone / follicle stimulating hormone ratio (LH / FSH ratio) was confirmed to decrease (Fig. 3).
실시예 4. 감태 추출물의 혈중 난포자극호르몬(follicular stimulating hormone) 변화 확인 Example 4. Confirmation of changes in follicular stimulating hormone in blood of Ecklonia cava extract
동물모델을 이용하여, 혈중 난포자극호르몬(follicular stimulating hormone) 의 함량 변화를 확인하였다. PCOS 유도된 1mg/kg/BW 레트로졸(letrozole)의 투여군에서는 혈중 난포자극호르몬(follicular stimulating hormone)의 함량이 통계적으로 유의미하게 감소하였고, 본 발명의 500mg/kg/BW 감태(Ecklonia cava) 추출물이 혼합된 실험군(PCOS+EC500)과 0.1mg/kg/BW 레트로졸(letrozole) SR 펠릿에 1mg/kg/BW 레트로졸(letrozole) 처치 후 자연회복군이 혼합된 실험군(PCOS+positive)에서 혈중 난포자극호르몬(follicular stimulating hormone)이 증가하였다는 것을 확인하였다(도 4). Animal models were used to determine changes in the content of follicular stimulating hormone in the blood. In the PCOS-induced 1 mg / kg / BW letrozole group, the blood follicle stimulating hormone content was significantly reduced, and the 500 mg / kg / BW Ecklonia cava of the present invention was Ecklonia. cava ) Experimental group (PCOS + EC500) and 0.1mg / kg / BW letrozole SR pellets treated with 1mg / kg / BW letrozole treatment group, natural recovery group mixed (PCOS + positive) In the blood follicle stimulating hormone (follicular stimulating hormone) was confirmed that the increase (Fig. 4).
실시예Example 5. 혈중 테스토스테론(testosterone) 감소 효과 5. Blood testosterone reduction effect
동물모델을 이용하여, 혈중 테스토스테론(testosterone)의 함량 변화를 확인하였다. PCOS 유도된 1mg/kg/BW 레트로졸(letrozole)의 투여군(PCOS)에서는 혈중 테스토스테론(testosterone)의 함량이 통계적으로 유의미하게 증가하였고, 본 발명의 500mg/kg/BW 감태(Ecklonia cava) 추출물이 혼합된 실험군(PCOS+EC500)과 0.1mg/kg/BW 레트로졸(letrozole) SR 펠릿에 1mg/kg/BW 레트로졸(letrozole) 처치 후 자연회복군이 혼합된 실험군(PCOS+positive)에서 혈중 테스토스테론(testosterone)이 감소하였다는 것을 확인하였다(도 5). Animal models were used to confirm changes in the content of testosterone in the blood. In the PCOS-derived group of 1 mg / kg / BW letrozole (PCOS), the testosterone content in the blood was statistically increased, and the 500 mg / kg / BW Ecklonia cava ( Ecklonia ) of the present invention was significantly increased. cava ) Experimental group (PCOS + EC500) and 0.1mg / kg / BW letrozole SR pellets treated with 1mg / kg / BW letrozole treatment group, natural recovery group mixed (PCOS + positive) It was confirmed that the testosterone (testosterone) in the blood is reduced (Fig. 5).
실시예Example 6. 난소 내  6. Within the ovary 난포낭Follicle 수에 대한 효과 Effect on Number
감태 추출물의 난소 내 난포낭 수에 대한 효과를 조사한 결과, 하기 표 1에 나타난 바와 같이, 레트로졸(letrozole) 단독(PCOS)과 비교하여 감태 추출물과 레트로졸(letrozole) 혼합물을 처리한 실험군(PCOS+EC500)의 난소 내 난포낭 수가 현저히 감소하는 것을 확인할 수 있었다.As a result of investigating the effect of the Ecklonia cava extract on the number of follicles in the ovary, as shown in Table 1 below, the experimental group treated with the Ecklonia cava extract and letrozole mixture as compared to letrozole alone (PCOS) (PCOS) + EC500) significantly reduced the number of follicular follicles in the ovary.
난소 내 난포낭(follicular cyst) 수 감소Reduced number of follicular cysts in the ovary
CONCON PCOSPCOS PCOS+EC500PCOS + EC500 PCOS+positivePCOS + positive
난포낭 수Follicle count 1.75±1.181.75 ± 1.18 17.50±2.53* 17.50 ± 2.53 * 7.00±0.40# 7.00 ± 0.40 # 3.00±0.91# 3.00 ± 0.91 #
*P < 0.05 versus CON, # P < 0.05 versus PCOS* P <0.05 versus CON, # P <0.05 versus PCOS

Claims (8)

  1. 감태(Ecklonia cava) 추출물을 유효성분으로 포함하는 다낭성 난소 증후군(polycystic ovary syndrome) 관련 질환의 예방 또는 치료용 약학 조성물. Ecklonia cava ) A pharmaceutical composition for the prevention or treatment of polycystic ovary syndrome-related diseases comprising the extract as an active ingredient.
  2. 제1항에 있어서, 상기 감태 추출물의 용매는 물, C1~C4의 저급 알코올 또는 이들의 혼합물인 것을 특징으로 하는 다낭성 난소 증후군 관련 질환의 예방 또는 치료용 약학 조성물.According to claim 1, wherein the solvent of the Ecklonia cava extract is water, lower alcohol of C 1 ~ C 4 or a mixture thereof, The pharmaceutical composition for preventing or treating polycystic ovary syndrome-related diseases.
  3. 제1항에 있어서, 상기 다낭성 난소 증후군 관련 질환은 난소부전에 의한 것임을 특징으로 하는 다낭성 난소 증후군 관련 질환의 예방 또는 치료용 약학 조성물.According to claim 1, wherein the polycystic ovary syndrome-related disease is a pharmaceutical composition for preventing or treating polycystic ovary syndrome-related diseases, characterized in that due to ovarian failure.
  4. 제1항에 있어서, 상기 다낭성 난소 증후군 관련 질환은 고안드로겐 혈증, 무월경, 과소월경, 기능 이상성 자궁출혈, 조기폐경, 난임 및 자궁내막증중에서 선택된 하나 이상인 것을 특징으로 하는 다낭성 난소 증후군 관련 질환의 예방 또는 치료용 약학 조성물.The method of claim 1, wherein the polycystic ovary syndrome-related disease is at least one selected from pyrogenemia, amenorrhea, hypermenorrhea, dysfunctional uterine bleeding, premature menopause, infertility, and endometriosis. Therapeutic pharmaceutical composition.
  5. 제1항에 있어서, 상기 감태 추출물 이외에 추가로 담체, 부형제 또는 희석제를 더 포함하는 것을 특징으로 하는 다낭성 난소 증후군 관련 질환의 예방 또는 치료용 약학 조성물.The method of claim 1, wherein in addition to the Ecklonia cava extract, a carrier, excipient or diluent further comprises a pharmaceutical composition for preventing or treating polycystic ovary syndrome-related diseases.
  6. 감태(Ecklonia cava) 추출물을 유효성분으로 포함하는 다낭성난소 증후군(polycystic ovary syndrome) 관련 질환의 예방 또는 개선용 건강기능식품 조성물. Ecklonia cava ) Health functional food composition for the prevention or improvement of diseases related to polycystic ovary syndrome (polycystic ovary syndrome) comprising the extract as an active ingredient.
  7. 제6항에 있어서, 상기 다낭성 난소 증후군 관련 질환은 고안드로겐 혈증, 무월경, 과소월경, 기능 이상성 자궁출혈, 조기폐경, 난임 및 자궁내막증 중에서 선택된 하나 이상인 것을 특징으로 하는 다낭성 난소 증후군 관련 질환의 예방 또는 개선용 건강기능식품 조성물.7. The method of claim 6, wherein the polycystic ovary syndrome-related disease is at least one selected from folic acid, amenorrhea, hypermenorrhea, dysfunctional uterine bleeding, early menopause, infertility, and endometriosis. Health functional food composition for improvement.
  8. 제6항에 있어서, 상기 조성물은 분말, 과립, 환, 정제, 캡슐, 캔디, 시럽 및 음료 중에서 선택된 어느 하나의 제형으로 제조되는 것을 특징으로 하는 다낭성 난소 증후군 관련 질환의 예방 또는 개선용 건강기능식품 조성물.According to claim 6, wherein the composition is a powder, granules, pills, tablets, capsules, candy, syrups and beverages, health functional foods for preventing or ameliorating polycystic ovary syndrome-related diseases, characterized in that it is prepared in any one formulation. Composition.
PCT/KR2018/004237 2017-04-14 2018-04-11 Composition for preventing, ameliorating or treating polycystic ovary syndrome-related diseases comprising ecklonia cava extract as active ingredient WO2018190630A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170048334A KR101907849B1 (en) 2017-04-14 2017-04-14 Composition for preventing, improving or treating disorder associated with polycystic ovary syndrome comprising extract of Ecklonia cava as effective component
KR10-2017-0048334 2017-04-14

Publications (1)

Publication Number Publication Date
WO2018190630A1 true WO2018190630A1 (en) 2018-10-18

Family

ID=63792765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/004237 WO2018190630A1 (en) 2017-04-14 2018-04-11 Composition for preventing, ameliorating or treating polycystic ovary syndrome-related diseases comprising ecklonia cava extract as active ingredient

Country Status (2)

Country Link
KR (1) KR101907849B1 (en)
WO (1) WO2018190630A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113827611A (en) * 2021-11-16 2021-12-24 复旦大学附属妇产科医院 Application of seaweed extract GV971 in preparation of medicine for treating polycystic ovarian syndrome

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102159128B1 (en) 2018-12-07 2020-09-23 동신대학교산학협력단 Composition containing extract of mixture of kajime and red shell

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101613448B1 (en) * 2011-08-31 2016-05-02 한국해양대학교 산학협력단 n-Butanol substracts of Ecklonia cava for preventing obesity
KR20160094830A (en) * 2015-01-30 2016-08-10 안용석 Pharmaceutical composition comprising the fermentation extract of ecklonia cava as an effective component for prevention or treatment of thrombosis and health functional food comprising the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101613448B1 (en) * 2011-08-31 2016-05-02 한국해양대학교 산학협력단 n-Butanol substracts of Ecklonia cava for preventing obesity
KR20160094830A (en) * 2015-01-30 2016-08-10 안용석 Pharmaceutical composition comprising the fermentation extract of ecklonia cava as an effective component for prevention or treatment of thrombosis and health functional food comprising the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEE, S. -H .: "Anti-diabetic effects of brown algae derived phlorotannins, marine polyphenols through diverse mechanisms", FITOTERAPIA, 2013, pages 129 - 136, XP028579860, DOI: doi:10.1016/j.fitote.2013.02.013 *
LEE, S. -H.: "Effects of brown alga, Ecklonia cava on glucose and lipid metabolism in C57BL/KsJ-db/db mice, a model of type 2 diabetes mellitus", FOOD AND CHEMICAL TOXICOLOGY, 2012 *
OVALLE, F.: "Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus", FERTILITY AND STERILITY, 2002, pages 1095 - 1105 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113827611A (en) * 2021-11-16 2021-12-24 复旦大学附属妇产科医院 Application of seaweed extract GV971 in preparation of medicine for treating polycystic ovarian syndrome

Also Published As

Publication number Publication date
KR101907849B1 (en) 2018-10-12

Similar Documents

Publication Publication Date Title
US20100105766A1 (en) Composition for inhibition or prevention of bone density reduction
WO2015002391A1 (en) Composition having a function for alleviating premenstrual syndrome and menstrual pain
WO2016060426A1 (en) Composition containing dolichos lablab l. extract as active ingredient for preventing or alleviating non-alcoholic fatty liver diseases
WO2014058142A1 (en) Pharmaceutical composition containing aster glehni extract as active ingredientfor preventing or treating obesity or metabolic diseases
WO2018190630A1 (en) Composition for preventing, ameliorating or treating polycystic ovary syndrome-related diseases comprising ecklonia cava extract as active ingredient
WO2016159524A2 (en) Composition for alleviating ovarian aging, containing ginseng berry extract
KR101802675B1 (en) A herbal mixtuer extract with improved implantation and use thereof
WO2020091265A1 (en) Composition comprising elderberry extract as effective component for preventing, treating, or alleviating male climacteric syndrome
KR101860639B1 (en) Composition comprising extract of evodiae fructus having protective activity against ovotoxicity for preventing or treating premature menopause
KR101931226B1 (en) Composition for preventing, alleviating or treating disorder associated with polycystic ovary syndrome comprising extract of Cassiae Semen as effective component
WO2020241958A1 (en) Composition for preventing or treating woman menopause symptoms, comprising cordyceps militaris concentrate as active ingredient
KR101445966B1 (en) A composition comprising Amomum cardamomum L. extracts having anti-obesity activity
WO2021002547A1 (en) Composition for preventing, reducing or treating andropause syndrome, comprising scutellaria barbata extract as active ingredient
KR102070793B1 (en) Composition for preventing, alleviating or treating ovarian dysfunction comprising Allium fistulosum extract as effective component
WO2020122373A1 (en) Composition comprising glycyrrhiza uralensis extract as active ingredient for prevention, alleviation, or treatment of late-onset hypogonadism syndrome
WO2021070999A1 (en) Composition for preventing, ameliorating, or treating metabolic syndromes including obesity, diabetes, hyperlipidemia, and fatty liver
WO2020122385A1 (en) Composition comprising elecampane extract for alleviating premenstrual syndrome symptom
WO2018190631A1 (en) Composition for preventing, ameliorating or treating depression due to decrease in estrogen secretion containing tetragonia tetragonioides extract as active ingredient
KR20040082951A (en) Phytoestrogenic composition comprising an extract of chinese licorice root or isoliquiritin
CN114845707A (en) Composition for preventing or treating porcine epidemic diarrhea virus infection comprising complex comprising curcuminoid-based compound and licorice extract or fraction thereof
KR20210038099A (en) Composition for preventing, improving or treating bone disease comprising cricket extracts
KR20050003665A (en) Composition comprising an extract of Peucedanum japonicum for preventing and treating diabetes
KR100535322B1 (en) Pharmaceutical composition comprising the extract of Allium tuberosum Rottler for treating or preventing diabetes mellitus
KR20190118961A (en) Composition for Preventing or Improving Muscle Atrophy Comprising Kukoamine A and Kukoamine B
CN110404029B (en) Composition with blood sugar reducing effect and preparation method and application thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18783947

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18783947

Country of ref document: EP

Kind code of ref document: A1